Analyst Expectations For Lumos Pharma's Future
Portfolio Pulse from Benzinga Insights
Lumos Pharma (NASDAQ:LUMO) has been analyzed by 5 analysts, showing a range of ratings from bullish to bearish. Recent analyst actions include lowered price targets and ratings, with an average 12-month price target of $13.1, down from $23.00. The company faces financial challenges, including a decline in revenue growth and negative profitability metrics.
October 24, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lumos Pharma has received mixed analyst ratings, with recent downgrades in price targets and ratings. The average 12-month price target has dropped significantly, indicating potential short-term pressure on the stock. Financial challenges include declining revenue and negative profitability metrics.
The article highlights a significant drop in the average 12-month price target for Lumos Pharma, along with recent downgrades by analysts. This suggests a bearish sentiment in the short term. Additionally, the company's financial challenges, such as declining revenue and negative profitability metrics, further support the likelihood of downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100